Based on the data presented here, brigatinib possesses potent anti-tumor activity against NF2-deficient tumors via inhibition of multiple RTKs frequently activated in these tumors as well as blockade of several non-RTKs and serine-threonine kinases, but not ALK. This evidence concerns the gene MARK2 and neoplasm.